{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:09:05Z","timestamp":1758402545968},"reference-count":81,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapeutic drug monitoring (TDM), or the measurement of drug concentrations in blood and antidrug antibodies, for biologic therapies used to treat inflammatory bowel disease (IBD) is an area of growing interest within the IBD community. When there is a definable relationship between drug concentration and clinical effect, blood concentration of biologics (and antidrug antibodies assessment) could be used to predict patient response and to titrate the biologics to maximize therapeutic benefit. This dose individualization has been proven to be more efficacious and cost\u2010effective than empiric dose adjustment and can better guide therapeutic decisions regarding therapy withdrawal or switch. Appropriate implementation and interpretation of drug concentration measurement in TDM are essential to ensure full clinical benefit. Factors that need to be considered include sources of variability, timing of blood sampling, dosing history, analytical performance, immunogenicity, comedications, and clinical status of the patients. Desired target concentrations for biologics used in IBD have not been clearly determined yet. Published concentration thresholds differed widely for a given biologic, indicating a lack of consistent information. Factors other than drug concentration that may contribute to the dose\u2010response variation are largely missing in the current TDM setting. A target range is likely preferable to a single value for TDM of biologics in IBD, and additional prospective research needs to be conducted in order to establish these ranges. Moving forward, TDM may be combined with pharmacodynamic end points and modeling and simulation tools for improved therapeutic benefit in IBD.<\/jats:p>","DOI":"10.1002\/jcph.1084","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T19:55:20Z","timestamp":1519242920000},"page":"864-876","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?"],"prefix":"10.1002","volume":"58","author":[{"given":"Hannah","family":"Hoseyni","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Pharmacy  Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2008.025"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.06.032"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000867"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.21"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-017-0559-8"},{"key":"e_1_2_10_7_1","unstructured":"WangYMC.Regulatory perspectives of implementing TDM\u2010challenges and opportunities.ASCPT 2017 Annual Meeting Symposium.2017.http:\/\/www.ascpt.org\/Portals\/8\/docs\/Meetings\/2017%20Annual%20Meeting\/2017%20Presentations\/Friday%203_17\/Clinical%20Practice_Yow%20Ming%20Wang.pdf?ver=2017-03-30-081418-707Accessed October 8 2017."},{"key":"e_1_2_10_8_1","first-page":"A617","article-title":"Relationship between infliximab pharmacokinetics and improvement in Crohn's disease","volume":"122","author":"Fasanmade A","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)80303-7"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.07.032"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0718-4"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1892-1"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"S408","DOI":"10.1016\/S0016-5085(16)31423-8","article-title":"Population pharmacokinetic modeling analysis of golimumab in adult patients with moderately to severely active ulcerative colitis","volume":"150","author":"Adedokun OJ","year":"2016","journal-title":"Gastroenterology"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.491"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13243"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"S408","DOI":"10.1016\/S0016-5085(16)31422-6","article-title":"Pharmacokinetics and exposure\u2010response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: results from the UNITI\u20101, UNITI\u20102, and IM\u2010UNITI studies.","volume":"150","author":"Adedokun OJ","year":"2016","journal-title":"Gastroenterology"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9529-x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.10.014"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04946.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.181"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.07.005"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.9"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2009.24.1.1"},{"key":"e_1_2_10_25_1","first-page":"101","article-title":"Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases","volume":"9","author":"Dreesen E","year":"2017","journal-title":"Clin Pharmacol"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31826aabc3"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9534-0"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1286-y"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.10.019"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304094"},{"key":"e_1_2_10_31_1","first-page":"S24","article-title":"Drug\u2010concentration versus symptom\u2010driven dose adaptation of infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix).","volume":"10","author":"D'Haens G","year":"2016","journal-title":"J Crohns Colitis"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)60430-2"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)61470-X"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1873-9946(12)60353-5"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.06.025"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2010.536254"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.12"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)31549-4"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.035"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1873-9946(12)60011-7"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)61473-5"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307882"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)30370-X"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(14)60868-4"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)31553-6"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12869"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001182"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)31556-1"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.07.010"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(13)60334-0"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(13)62863-2"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw133"},{"key":"e_1_2_10_54_1","unstructured":"AdedokunOJ XuZ GasinkC et\u00a0al.Exposure\u2010response to SC ustekinumab in moderate\u2010severe Crohn's disease: results from the IM\u2010UNITI maintenance study.World Conference of Gastroenterology at ACG 2017. 2017. Abstract P1263.https:\/\/www.eventscribe.com\/2017\/wcogacg2017\/ajaxcalls\/PosterInfo.asp?efp=S1lVTUxLQVozODMy&PosterID=114906&rnd=0.9109643. Accessed November 1 2017."},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)31526-3"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)31541-X"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.10.025"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000182003.06031.00"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308099"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640613519626"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091973"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i3.293"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12142"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3386"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181cc6fef"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10302"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030452"},{"key":"e_1_2_10_68_1","first-page":"214","article-title":"Management of infliximab treated patients with psoriasis based on infliximab plasma levels and antibodies to infliximab","volume":"5","author":"Kozub P","year":"2014","journal-title":"J Clin Exp Dermatol Res"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2012.01679.x"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.04.014"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev298"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204172"},{"key":"e_1_2_10_74_1","first-page":"942","article-title":"Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice","volume":"32","author":"Rosas J","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1266-1"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305279"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.12.035"},{"key":"e_1_2_10_78_1","article-title":"Cost savings of anti\u2010TNF therapy using a test\u2010based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab","volume":"3","author":"Roblin X","year":"2015","journal-title":"J Mark Access Health Policy"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05689.x"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)30492-4"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12503"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9518-0"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.1084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T15:46:27Z","timestamp":1695397587000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1002\/jcph.1084"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1084","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]}}}